Core Laboratories (CLB)
(Real Time Quote from BATS)
$20.33 USD
+0.33 (1.65%)
Updated Jun 28, 2022 01:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Core Laboratories NV falls in the month of December .
All items in Millions except EPS data.
12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 | |
---|---|---|---|---|---|
Sales | 470 | 487 | 668 | 701 | 660 |
Cost Of Goods | 368 | 375 | 496 | 497 | 474 |
Gross Profit | 102 | 113 | 173 | 204 | 186 |
Selling & Adminstrative & Depr. & Amort Expenses | 57 | 189 | 76 | 85 | 73 |
Income After Depreciation & Amortization | 45 | -77 | 97 | 119 | 112 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 9 | 14 | 15 | 13 | 11 |
Pretax Income | 36 | -91 | 82 | 105 | 102 |
Income Taxes | 16 | 6 | -12 | 25 | 19 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 20 | -97 | 94 | 80 | 83 |
Extras & Discontinued Operations | 0 | 0 | 8 | 0 | 0 |
Net Income | 20 | -98 | 102 | 80 | 83 |
Depreciation Footnote | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 64 | -56 | 119 | 142 | 137 |
Depreciation & Amortization (Cash Flow) | 19 | 21 | 23 | 23 | 25 |
Income After Depreciation & Amortization | 45 | -77 | 97 | 119 | 112 |
Earnings Per Share Data | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Average Shares | 46.69 | 44.48 | 44.65 | 44.47 | 44.26 |
Diluted EPS Before Non-Recurring Items | 0.71 | 0.80 | 1.79 | 2.28 | 2.00 |
Diluted Net EPS | 0.42 | -2.20 | 2.28 | 1.79 | 1.88 |
Fiscal Year end for Core Laboratories NV falls in the month of December .
All items in Millions except EPS data.
3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | 3/31/21 | |
---|---|---|---|---|---|
Sales | 115.30 | 125.14 | 117.99 | 118.75 | 108.38 |
Cost Of Goods | 96.95 | 96.99 | 92.92 | 93.84 | 84.15 |
Gross Profit | 18.35 | 28.15 | 25.07 | 24.90 | 24.23 |
SG&A, R&D, and Dept/Amort Expenses | 18.74 | 13.95 | 18.43 | 12.10 | 12.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | -0.39 | 14.20 | 6.64 | 12.80 | 11.62 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 2.64 | 2.59 | 2.67 | 2.53 | 1.36 |
Pretax Income | -3.04 | 11.61 | 3.97 | 10.27 | 10.26 |
Income Taxes | -1.20 | 8.82 | 2.96 | 2.05 | 2.05 |
Minority Interest | 0.05 | 0.10 | 0.14 | 0.16 | 0.10 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.84 | 2.79 | 1.01 | 8.22 | 8.21 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | -1.89 | 2.69 | 0.87 | 8.06 | 8.11 |
Earnings Per Share Data | 3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | 3/31/21 |
---|---|---|---|---|---|
Average Shares | 46.30 | 46.93 | 47.13 | 47.10 | 45.96 |
Diluted EPS Before Non-Recurring Items | 0.08 | 0.20 | 0.18 | 0.18 | 0.15 |
Diluted Net EPS | -0.04 | 0.05 | 0.02 | 0.17 | 0.18 |